Click here to view online. Add this email to your safelist.
AstraZeneca continues strategic investment in China to accelerate delivery of innovative biologics and targeted medicines
16 December 2015
AstraZeneca, along with MedImmune, its global biologics research and development arm, today announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second largest market globally and a key growth platform.
|
|||||
|
|||||
|
For more information please visit AstraZeneca If you would like to unsubscribe click here |
